首页> 美国卫生研究院文献>Journal of Biomedical Research >Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
【2h】

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients

机译:新辅助化疗对525例中国乳腺癌患者激素受体和Ki67表达的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry. Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2% (79/521), 26.9% (140/520) and 44.8% (225/502), respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5% (39/521), 13.3% (69/520) and 21.1% (106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7% (40/521), 13.6% (71/520) and 23.7% (119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.
机译:本研究旨在研究新辅助化疗对中国女性乳腺癌患者激素受体和Ki67表达的影响。通过免疫组织化学研究了525例新辅助化疗患者中雌激素受体(ER),孕激素受体(PR)和Ki67的表达。观察到通过术前核心针穿刺活检和切除的组织活检制成的标本之间的差异。 ER,PR和Ki67在核心针穿刺活检和切除的组织活检中的阳性率分别为65.3%和63.2%,51.0%和42.6%,65.6%和43.4%。 ER,PR和Ki67在核心针穿刺活检和切除的组织活检中的表达无统计学差异。然而,在新辅助化疗后,ER,PR和Ki67的不一致率分别为15.2%(79/521),26.9%(140/520)和44.8%(225/502)。分别在7.5%(39/521),13.3%(69/520)和21.1%(106/502)的患者中ER,PR和Ki67状态从阳性更改为阴性,而ER,PR和Ki67状态从阴性更改为阴性分别有7.7%(40/521),13.6%(71/520)和23.7%(119/502)的患者呈阳性。这些结果表明,新辅助化疗后某些生物标志物的状态发生变化,需要重新检查生物标志物的状态以优化辅助性全身治疗和更好的预后评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号